CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Oraxoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03165955
NCT03165955Phase 1Completed
CompareCT.gov

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Health Hope Pharma·interventional·Posted May 24, 2017·Updated Mar 12, 2025

In Brief

A Phase 1 clinical trial evaluating Oraxol for Breastcancer. Completed, enrolled 28 participants across 6 sites.

Detailed Summary

This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel treatment is indicated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreastcancer
CountriesTaiwan
CollaboratorsPharmaEssentia

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 24, 2017
Enrollment StartMay 9, 2017
Primary CompletionNov 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.1 years ago

Interventions

Oraxoldrug

HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules